注意欠陥・多動性障害(ADHD):治療薬開発パイプライン動向(2014年下半期版)

調査会社Global Markets Direct社が発行したリサーチレポート(データ管理コード:GMDHC5446IDB)
◆英語タイトル:Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2014
◆発行会社/調査会社:Global Markets Direct
◆商品コード:GMDHC5446IDB
◆発行日:2014年9月30日
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆ページ数:151
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥226,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥678,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[注意欠陥・多動性障害(ADHD):治療薬開発パイプライン動向(2014年下半期版)]についてメールでお問い合わせはこちら
当調査レポートでは、世界における注意欠陥・多動性障害(ADHD)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・注意欠陥・多動性障害(ADHD)の概要
・注意欠陥・多動性障害(ADHD)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・注意欠陥・多動性障害(ADHD)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・企業別、開発中の製品
・大学/研究機関別、研究中の製品
・注意欠陥・多動性障害(ADHD)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・注意欠陥・多動性障害(ADHD)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
*** レポート概要(サマリー)***

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline Review, H2 2014’, provides an overview of the Attention Deficit Hyperactivity Disorder (ADHD)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Attention Deficit Hyperactivity Disorder (ADHD)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Attention Deficit Hyperactivity Disorder (ADHD) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Attention Deficit Hyperactivity Disorder (ADHD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Attention Deficit Hyperactivity Disorder (ADHD) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Attention Deficit Hyperactivity Disorder (ADHD) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

*** レポート目次(コンテンツ)***

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 7
Global Markets Direct Report Coverage 7
Attention Deficit Hyperactivity Disorder (ADHD) Overview 8
Therapeutics Development 9
Pipeline Products for Attention Deficit Hyperactivity Disorder (ADHD) – Overview 9
Pipeline Products for Attention Deficit Hyperactivity Disorder (ADHD) – Comparative Analysis 10
Attention Deficit Hyperactivity Disorder (ADHD) – Therapeutics under Development by Companies 11
Attention Deficit Hyperactivity Disorder (ADHD) – Therapeutics under Investigation by Universities/Institutes 14
Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Attention Deficit Hyperactivity Disorder (ADHD) – Products under Development by Companies 19
Attention Deficit Hyperactivity Disorder (ADHD) – Products under Investigation by Universities/Institutes 22
Attention Deficit Hyperactivity Disorder (ADHD) – Companies Involved in Therapeutics Development 23
DURECT Corporation 23
Eli Lilly and Company 24
Taisho Pharmaceutical Co., Ltd. 25
NeuroDerm Ltd. 26
Takeda Pharmaceutical Company Limited 27
Richter Gedeon Nyrt. 28
Pfizer Inc. 29
Purdue Pharma L.P. 30
Shire Plc 31
Vernalis plc 32
Collegium Pharmaceutical, Inc. 33
Hisamitsu Pharmaceutical Co., Inc. 34
Arbor Pharmaceuticals, LLC. 35
Curemark, LLC 36
Supernus Pharmaceuticals, Inc. 37
Intra-Cellular Therapies, Inc. 38
Tris Pharma, Inc. 39
Neos Therapeutics, Inc. 40
KemPharm, Inc. 41
Otsuka Holdings Co., Ltd. 42
Reviva Pharmaceuticals Inc. 43
Amarantus Bioscience Holdings, Inc. 44
Mnemosyne Pharmaceuticals, Inc. 45
Alcobra Ltd 46
Sunovion Pharmaceuticals Inc. 47
Signature Therapeutics, Inc 48
P2D Bioscience 49
Attention Deficit Hyperactivity Disorder (ADHD) – Therapeutics Assessment 50
Assessment by Monotherapy Products 50
Assessment by Target 51
Assessment by Mechanism of Action 54
Assessment by Route of Administration 57
Assessment by Molecule Type 59
Drug Profiles 60
amfetamine XR – Drug Profile 60
SHP-465 – Drug Profile 61
dasotraline – Drug Profile 62
methylphenidate hydrochloride – Drug Profile 63
guanfacine hydrochloride ER – Drug Profile 64
CM-4612 – Drug Profile 66
methylphenidate hydrochloride – Drug Profile 67
TRI-102 – Drug Profile 68
methylphenidate hydrochloride XR – Drug Profile 69
methylphenidate hydrochloride – Drug Profile 70
methylphenidate hydrochloride ER – Drug Profile 71
edivoxetine – Drug Profile 72
brexpiprazole – Drug Profile 74
dextroamphetamine – Drug Profile 76
eltoprazine – Drug Profile 77
lisdexamfetamine dimesylate – Drug Profile 78
SPN-812 – Drug Profile 82
ND-0801 – Drug Profile 83
Metadoxine ER – Drug Profile 84
AR-08 – Drug Profile 86
centanafadine SR – Drug Profile 87
dextroamphetamine MR – Drug Profile 88
V-81444 – Drug Profile 89
centanafadine – Drug Profile 90
PBF-509 – Drug Profile 91
IPX-233 – Drug Profile 92
TAK-137 – Drug Profile 93
COL-171 – Drug Profile 94
ITI-214 – Drug Profile 95
Small Molecule to Inhibit A2A Receptor for CNS Disorders – Drug Profile 96
PD-2005 – Drug Profile 97
PD-2007 – Drug Profile 98
KP-415 – Drug Profile 99
PFR-08001 – Drug Profile 100
MGS-0028 – Drug Profile 101
PFR-8026 – Drug Profile 102
BLI-1008 – Drug Profile 103
methylphenidate hydrochloride – Drug Profile 104
Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders – Drug Profile 105
RP-14000 – Drug Profile 106
RGH-235 – Drug Profile 107
Small Molecule to Agonize NMDA2D for ADHD – Drug Profile 108
Small Molecules to Inhibit Sodium Hydrogen Exchanger for ADHD – Drug Profile 109
Small Molecules to Antagonize H3 Receptor for ADHD And Alzheimers Disease – Drug Profile 110
Small Molecules to Modulate Choline Transporter for ADHD – Drug Profile 111
Small Molecules to Antagonize Dopamine D4 Receptor for ADHD – Drug Profile 112
RP-5063 – Drug Profile 113
Small Molecule for ADHD – Drug Profile 114
etiguanfacine – Drug Profile 115
Drug for Attention Deficit Hyperactivity Disorder – Drug Profile 116
Attention Deficit Hyperactivity Disorder (ADHD) – Recent Pipeline Updates 117
Attention Deficit Hyperactivity Disorder (ADHD) – Dormant Projects 137
Attention Deficit Hyperactivity Disorder (ADHD) – Discontinued Products 138
Attention Deficit Hyperactivity Disorder (ADHD) – Product Development Milestones 139
Featured News & Press Releases 139
Appendix 147
Methodology 147
Coverage 147
Secondary Research 147
Primary Research 147
Expert Panel Validation 147
Contact Us 148
Disclaimer 148

[List of Tables]
Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD), H2 2014 12
Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD) - Comparative Analysis, H2 2014 13
Number of Products under Development by Companies, H2 2014 15
Number of Products under Investigation by Universities/Institutes, H2 2014 17
Comparative Analysis by Late Stage Development, H2 2014 18
Comparative Analysis by Clinical Stage Development, H2 2014 19
Comparative Analysis by Early Stage Development, H2 2014 20
Comparative Analysis by Unknown Stage Development, H2 2014 21
Products under Development by Companies, H2 2014 22
Products under Development by Companies, H2 2014 (Contd..1) 23
Products under Development by Companies, H2 2014 (Contd..2) 24
Products under Investigation by Universities/Institutes, H2 2014 25
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by DURECT Corporation, H2 2014 26
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Eli Lilly and Company, H2 2014 27
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Taisho Pharmaceutical Co., Ltd., H2 2014 28
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by NeuroDerm Ltd., H2 2014 29
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 30
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Richter Gedeon Nyrt., H2 2014 31
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Pfizer Inc., H2 2014 32
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Purdue Pharma L.P., H2 2014 33
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Shire Plc, H2 2014 34
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Vernalis plc, H2 2014 35
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Collegium Pharmaceutical, Inc., H2 2014 36
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Hisamitsu Pharmaceutical Co., Inc., H2 2014 37
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Arbor Pharmaceuticals, LLC., H2 2014 38
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Curemark, LLC, H2 2014 39
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Supernus Pharmaceuticals, Inc., H2 2014 40
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Intra-Cellular Therapies, Inc., H2 2014 41
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Tris Pharma, Inc., H2 2014 42
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Neos Therapeutics, Inc., H2 2014 43
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by KemPharm, Inc., H2 2014 44
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Otsuka Holdings Co., Ltd., H2 2014 45
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Reviva Pharmaceuticals Inc., H2 2014 46
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Amarantus Bioscience Holdings, Inc., H2 2014 47
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Mnemosyne Pharmaceuticals, Inc., H2 2014 48
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Alcobra Ltd, H2 2014 49
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Sunovion Pharmaceuticals Inc., H2 2014 50
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Signature Therapeutics, Inc, H2 2014 51
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by P2D Bioscience, H2 2014 52
Assessment by Monotherapy Products, H2 2014 53
Number of Products by Stage and Target, H2 2014 56
Number of Products by Stage and Mechanism of Action, H2 2014 59
Number of Products by Stage and Route of Administration, H2 2014 61
Number of Products by Stage and Molecule Type, H2 2014 62
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics - Recent Pipeline Updates, H2 2014 120
Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects, H2 2014 140
Attention Deficit Hyperactivity Disorder (ADHD) - Discontinued Products, H2 2014 141

[List of Figures]
Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD), H2 2014 12
Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD) - Comparative Analysis, H2 2014 13
Number of Products under Development by Companies, H2 2014 14
Number of Products under Investigation by Universities/Institutes, H2 2014 17
Comparative Analysis by Late Stage Development, H2 2014 18
Comparative Analysis by Clinical Stage Development, H2 2014 19
Comparative Analysis by Early Stage Products, H2 2014 20
Assessment by Monotherapy Products, H2 2014 53
Number of Products by Top 10 Target, H2 2014 54
Number of Products by Stage and Top 10 Target, H2 2014 55
Number of Products by Top 10 Mechanism of Action, H2 2014 57
Number of Products by Stage and Top 10 Mechanism of Action, H2 2014 58
Number of Products by Top 10 Route of Administration, H2 2014 60
Number of Products by Stage and Top 10 Route of Administration, H2 2014 61
Number of Products by Stage and Top 10 Molecule Type, H2 2014 62

*** 掲載企業 ***

DURECT Corporation
Eli Lilly and Company
Taisho Pharmaceutical Co., Ltd.
NeuroDerm Ltd.
Takeda Pharmaceutical Company Limited
Richter Gedeon Nyrt.
Pfizer Inc.
Purdue Pharma L.P.
Shire Plc
Vernalis plc
Collegium Pharmaceutical, Inc.
Hisamitsu Pharmaceutical Co., Inc.
Arbor Pharmaceuticals, LLC.
Curemark, LLC
Supernus Pharmaceuticals, Inc.
Intra-Cellular Therapies, Inc.
Tris Pharma, Inc.
Neos Therapeutics, Inc.
KemPharm, Inc.
Otsuka Holdings Co., Ltd.
Reviva Pharmaceuticals Inc.
Amarantus Bioscience Holdings, Inc.
Mnemosyne Pharmaceuticals, Inc.
Alcobra Ltd
Sunovion Pharmaceuticals Inc.
Signature Therapeutics, Inc
P2D Bioscience

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(GMDHC5446IDB )"注意欠陥・多動性障害(ADHD):治療薬開発パイプライン動向(2014年下半期版)" (英文:Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2014)はGlobal Markets Direct社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。